Get the app
US › Healthcare

ImageneBio, Inc. (IMA)

US · Healthcare · Biotechnology

$5.02+1.83%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.2M
EPS
$-0.63
EPS estimate
$-0.90

EPS came in at -0.63 against a street estimate of -0.90 — a beat of 30.0%.

Key statistics

Market cap
$56.1M
Forward P/E
0.0
P/B
0.40
Book value
$12.60
EPS (TTM)
$-4.73
52-week high
$9.10
52-week low
$3.94
50-day MA
$5.55
200-day MA
$5.98

Analyst view

with an average price target of $18.00.

Shareholding

Insiders
15.70%
Institutions
54.50%

Largest institutional holders

FundStake
Bvf Inc9.78%
Blue Owl Capital Holdings LP8.08%
Cable Car Capital LLC6.65%
Omega Fund Management LLC4.01%
Orbimed Advisors LLC3.33%
RTW INVESTMENTS, LLC2.95%
Vanguard Capital Management, LLC2.86%
Trails Edge Capital Partners, LP2.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ImageneBio, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.